OBJECTIVE: Residual immune activation and skewed T cell maturation may contribute to excess comorbidity and mortality in successfully treated HIV-infected patients, and long-term effects of combination antiretroviral therapy (cART) on immune reconstitution remain a debated issue. Quantitative T cell reconstitution and activation and its association with residual viremia in patients with 12 years of viremic suppression were investigated. DESIGN: Blood samples collected cross-sectionally from 71 HIV-infected patients with cART-induced viremic suppression through 12 years were compared with samples from 16 healthy controls. METHODS: Several different subsets of naive, memory, and activated T cells were analyzed in fresh whole blood by 6-color flowcytometry, and ultrasensitive quantification of HIV RNA was performed. RESULTS: HIV-infected patients had lower absolute and relative CD4 T cell counts and higher absolute and relative CD8 T cell counts than controls. HIV-infected patients had lower concentrations of naive CD4 cells than controls, but proportions were similar. HIV-infected patients had higher concentrations of CD8 T cells than controls in all the examined subsets but only a higher proportion of CD8 cells in the intermediately differentiated and activated subsets. Residual viremia did not correlate to proportions of naive CD4, CD4 recent thymic emigrants, or activated CD8 T cells. CONCLUSIONS: This study demonstrated some degree of T cell imbalance even after 12 years of successful cART. Large longitudinal studies are needed to establish whether these discrete changes have clinical relevance.
OBJECTIVE: Residual immune activation and skewed T cell maturation may contribute to excess comorbidity and mortality in successfully treated HIV-infectedpatients, and long-term effects of combination antiretroviral therapy (cART) on immune reconstitution remain a debated issue. Quantitative T cell reconstitution and activation and its association with residual viremia in patients with 12 years of viremic suppression were investigated. DESIGN: Blood samples collected cross-sectionally from 71 HIV-infectedpatients with cART-induced viremic suppression through 12 years were compared with samples from 16 healthy controls. METHODS: Several different subsets of naive, memory, and activated T cells were analyzed in fresh whole blood by 6-color flowcytometry, and ultrasensitive quantification of HIV RNA was performed. RESULTS:HIV-infectedpatients had lower absolute and relative CD4 T cell counts and higher absolute and relative CD8 T cell counts than controls. HIV-infectedpatients had lower concentrations of naive CD4 cells than controls, but proportions were similar. HIV-infectedpatients had higher concentrations of CD8 T cells than controls in all the examined subsets but only a higher proportion of CD8 cells in the intermediately differentiated and activated subsets. Residual viremia did not correlate to proportions of naive CD4, CD4 recent thymic emigrants, or activated CD8 T cells. CONCLUSIONS: This study demonstrated some degree of T cell imbalance even after 12 years of successful cART. Large longitudinal studies are needed to establish whether these discrete changes have clinical relevance.
Authors: Bret J Rudy; Bill G Kapogiannis; Carol Worrell; Kathleen Squires; James Bethel; Su Li; Craig M Wilson; Allison Agwu; Patricia Emmanuel; Georgine Price; Stephanie Hudey; Maureen M Goodenow; John W Sleasman Journal: J Acquir Immune Defic Syndr Date: 2015-05-01 Impact factor: 3.731
Authors: Allan R Tenorio; Yu Zheng; Ronald J Bosch; Supriya Krishnan; Benigno Rodriguez; Peter W Hunt; Jill Plants; Arjun Seth; Cara C Wilson; Steven G Deeks; Michael M Lederman; Alan L Landay Journal: J Infect Dis Date: 2014-05-01 Impact factor: 5.226
Authors: Wei Cao; Vikram Mehraj; Benoit Trottier; Jean-Guy Baril; Roger Leblanc; Bertrand Lebouche; Joseph Cox; Cecile Tremblay; Wei Lu; Joel Singer; Taisheng Li; Jean-Pierre Routy; S Vézina; L Charest; M Milne; E Huchet; S Lavoie; J Friedman; M Duchastel; F Villielm; P Côté; M Potter; B Lessard; M A Charron; S Dufresne; M E Turgeon; D Rouleau; L Labrecque; C Fortin; A de Pokomandy; V Hal-Gagné; M Munoz; B Deligne; V Martel-Laferrière; N Gilmore; M Fletcher; J Szabo Journal: Clin Infect Dis Date: 2015-09-08 Impact factor: 9.079
Authors: F De Salvador-Guillouët; C Sakarovitch; J Durant; K Risso; E Demonchy; P M Roger; E Fontas Journal: PLoS One Date: 2015-10-20 Impact factor: 3.240